Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
May 08 2024 - 9:00AM
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company
developing transformative cell and exosome-based therapeutics for
the treatment of rare diseases, today announced that the Company is
scheduled to present at various upcoming scientific and medical
conferences.
Event: |
American Society of Gene & Cell Therapy (ASGCT) 27th
Annual Meeting (Baltimore, MD) |
Date: |
May 7–11, 2024 |
Format: |
Oral Presentation/Abstract:
Exosome-mediated intracellular delivery of arginase-1: a potential
application for the treatment of Arginase-1 Deficiency |
|
|
Event: |
Parent Project Muscular
Dystrophy (PPMD) Cardiac Workshop III (Baltimore, MD) |
Date: |
May 9–10, 2024 |
Format: |
Panel: Industry perspectives on
cardiac monitoring in DMD clinical trials |
|
|
Event: |
International Society of
Extracellular Vesicles (ISEV) 2024 Meeting (Melbourne,
Australia) |
Date: |
May 9–12, 2024 |
Format: |
Abstract: Targeted cargo delivery
to mouse lower limb by exosomes carrying a muscle targeting moiety
with intravenous injection |
|
|
Event: |
CureDuchenne 2024 FUTURES
National Conference (Orlando, FL) |
Date: |
May 23–26, 2024 |
Format: |
Presentation: CAP-1002: an
allogeneic cell therapy demonstrates disease modification in
later-stage DMD patients: 24-month safety and efficacy results from
the HOPE-2 open label extension |
|
|
Event: |
International Society for
Cell & Gene Therapy (ISCT) 2024 Meeting (Vancouver,
Canada) |
Date: |
May 29–June 1, 2024 |
Format: |
Oral Presentation/Abstract:
Targeted delivery of ASO using exosomes leads to mouse dystrophin
exon skipping |
|
|
The posters and/or abstracts will be made
available on the publications section of the Capricor website
following the conclusion of the meetings.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a
biotechnology company dedicated to advancing transformative cell
and exosome-based therapeutics to redefine the treatment landscape
for rare diseases. At the forefront of our innovation is our lead
product candidate, CAP-1002 — an allogeneic cardiac-derived cell
therapy. Extensive preclinical and clinical studies have shown
CAP-1002 to demonstrate immunomodulatory, antifibrotic, and
regenerative actions specifically tailored for dystrophinopathies
and heart disease. CAP-1002 is currently advancing through Phase 3
clinical development for the treatment of Duchenne muscular
dystrophy (DMD). Capricor is also harnessing the power of our
exosome technology, using our proprietary StealthX™ platform in
preclinical development focused on the areas of vaccinology,
targeted delivery of oligonucleotides, proteins and small molecule
therapeutics to potentially treat and prevent a diverse array of
diseases. At Capricor, we stand committed to pushing the boundaries
of possibility and forging a path toward transformative treatments
for those in need. For more information, visit capricor.com,
and follow Capricor
on Facebook, Instagram and Twitter.
Cautionary Note Regarding
Forward-Looking Statements
Statements in this press release regarding the
efficacy, safety, and intended utilization of Capricor’s product
candidates; the initiation, conduct, size, timing and results of
discovery efforts and clinical trials; the pace of enrollment of
clinical trials; plans regarding regulatory filings, future
research and clinical trials; regulatory developments involving
products, including the ability to obtain regulatory approvals or
otherwise bring products to market; manufacturing capabilities;
dates for regulatory meetings; statements about our financial
outlook; the ability to achieve product milestones and to receive
milestone payments from commercial partners; plans regarding
current and future collaborative activities and the ownership of
commercial rights; scope, duration, validity and enforceability of
intellectual property rights; future revenue streams and
projections; expectations with respect to the expected use of
proceeds from the recently completed offerings and the anticipated
effects of the offerings; and any other statements about Capricor’s
management team’s future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words “believes,” “plans,” “could,”
“anticipates,” “expects,” “estimates,” “should,” “target,” “will,”
“would” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements. More
information about these and other risks that may impact Capricor’s
business is set forth in Capricor’s Annual Report on Form 10-K for
the year ended December 31, 2023, as filed with the Securities and
Exchange Commission on March 11, 2024. All forward-looking
statements in this press release are based on information available
to Capricor as of the date hereof, and Capricor assumes no
obligation to update these forward-looking statements.
Capricor has entered into
a partnership for the exclusive commercialization and
distribution of CAP-1002 for DMD in the United States and Japan
with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma,
Inc.), subject to regulatory approval. CAP-1002 is an
Investigational New Drug and is not approved for any indications.
None of Capricor’s exosome-based candidates have been approved for
clinical investigation.
For more information, please
contact:
Capricor Company Contact:AJ
Bergmann, Chief Financial Officerabergmann@capricor.com
858.727.1755
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Sep 2023 to Sep 2024